Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study.

"Declarations Ethics approval and consent to participateAll procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. This study was approved by the Ethics Committee of Fujian Cancer Hospital (SQ2017-015–01). Written informed consent was waived by the Ethics Committee of Fujian Cancer Hospital due to the retrospective nature of the study. Meanwhile, the institutional review boards of the other participating sites waived the ethics requirement, given the role of the research assistants in the study. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported by Fujian Provincial Natural Science Foundation (grant 2020J011120), National Natural Science Foundation of China (grant 82072565), Bejing Xisike Clinical Oncology Research Foundation (grant Y-2019AZZD-0386) and National Natural Science Foundation of China (grant number 82372954). The funders did not participate in the study design, data collection, analysis, decision to publish, or preparation of the manuscript."